Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price?
Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy are the most commonly recognized types of primary glomerulonephritis that progress to end-stage renal disease. Persistent proteinuria is a major determinant of such progression. Reduction of proteinuria slows progression of renal disease and improves renal survival, but many of the agents used to reduce proteinuria carry a considerable risk of toxicity. The assessment of benefit versus risk of these medications can be further complicated by the temporal disconnect between the onset of benefit and of serious adverse events. In addition, relapses are common in these disorders and there is often a need for retreatment. Such retreatment might lead to repeated and/or prolonged drug exposure and to the oversight or underestimation of the cumulative dose of these agents because of the potentially extended interval between relapses. Consequently, it is very important to constantly review each patient's status and take into account their age, comorbid conditions and cumulative drug exposure when assessing treatment options. The potentially delayed development of adverse events also emphasizes the need for long-term surveillance of patients who receive immunosuppressive treatment for glomerular disease, often well beyond their drug exposure period and even when the treatment has been successful.
Philibert
David
D
University Health Network, Toronto General Research Institute, Toronto, ON, Canada.
Cattran
Daniel
D
D000477:Alkylating Agents / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D005921:Glomerulonephritis / Q000150:complications* / Q000188:drug therapy*; D005922:Glomerulonephritis, IGA / Q000150:complications / Q000188:drug therapy; D015433:Glomerulonephritis, Membranous / Q000150:complications / Q000188:drug therapy; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology*; D012074:Remission Induction; D012307:Risk Factors
D000477:Alkylating Agents; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid